Divya Doval
Overview
Explore the profile of Divya Doval including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yadav S, Raj R, Uppuluri R, Choudhary D, Doval D, Dua V, et al.
Pediatr Hematol Oncol
. 2023 Nov;
41(2):169-171.
PMID: 38013455
No abstract available.
2.
Choudhary D, Doval D, Khandelwal V, Setia R, Handoo A
Blood Cell Ther
. 2023 Jun;
6(1):5-10.
PMID: 37324569
Introduction: Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment option for myelofibrosis (MF). Despite the benefits of long-term relapse-free survival, HSCT can be associated with substantial...
3.
Choudhury D, Kumar M, Sharma S, Khandelwal V, Doval D, Dadu T, et al.
Blood Cell Ther
. 2023 Jun;
3(2):32-36.
PMID: 37313366
Introduction: Stem cell transplantation is the cornerstone of therapy for transplant-eligible patients with severe aplastic anemia. Materials And Methods: Patients with severe aplastic anemia undergoing stem cell transplantation (including matched...
4.
Choudhary D, Doval D, Sharma S, Khandelwal V, Setia R, Handoo A
Blood Cell Ther
. 2023 Jan;
4(2):29-34.
PMID: 36712899
We report herein haplo-identical hematopoietic stem cell transplantation (haplo-HSCT) by T-cell replete graft infusion, with post-transplant cyclophosphamide (PTCy) in patients with hemoglobinopathies. Patients received a conditioning regimen consisting of either...
5.
Sharma S, Choudhary D, Doval D, Khandelwal V, Setia R, Dadu T, et al.
South Asian J Cancer
. 2022 Jul;
11(1):62-67.
PMID: 35833052
Sanjeev Kumar SharmaHematopoietic stem cell transplantation (HSCT) is the preferred treatment for high-risk and relapsed/refractory hematological malignancies. Moreover, with the improved supportive care and increasing acceptance of haploidentical transplantations as...
6.
Agrawal N, Singh R, Sharma S, Naithani R, Bhargava R, Choudhary D, et al.
Indian J Hematol Blood Transfus
. 2021 Jul;
38(2):388-393.
PMID: 34305341
COVID-19, caused by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 9, 2020. Hematopoietic stem-cell transplantation (HSCT) recipients...
7.
Sharma S, Choudhary D, Doval D, Khandelwal V, Patel A, Setia R, et al.
Indian J Hematol Blood Transfus
. 2021 Jul;
37(3):472-478.
PMID: 34267469
The conditioning regimens used for the allo-HSCT include either myeloablative conditioning (MAC) or reduced intensity conditioning (RIC) regimens based on the age, performance status and co-morbidities. Studies comparing the survival...
8.
Borah P, Mirgh S, Sharma S, Bansal S, Dixit A, Dolai T, et al.
Blood Cells Mol Dis
. 2020 Dec;
87:102525.
PMID: 33338697
Background: There is scarcity of data on outcome of COVID-19 in patients with hematological malignancies. Primary objective of study was to analyse the 14-day and 28-day mortality. Secondary objectives were...
9.
Khandelwal V, Choudhary D, Sharma S, Doval D, Bala S, Handoo A, et al.
Pediatr Blood Cancer
. 2020 Oct;
68(3):e28746.
PMID: 33001580
No abstract available.
10.
Khandelwal V, Sharma S, Doval D, Kumar M, Choudhary D, Sharma R, et al.
Indian J Hematol Blood Transfus
. 2020 Jul;
36(3):588-589.
PMID: 32647443
No abstract available.